A systematic review of the effectiveness of adalimumab

arthritis: a 12-week, double-blind, randomized,
placebo-controlled study. J Formos Med Assoc 2004;
103:618–23.
131. van Laar JM, Verburg RJ, Fibbe WE, Breedveld FC.
Intensive immunosuppression and autologous
stem cell transplantation for patients with severe
rheumatoid arthritis: the Leiden experience.
J Rheumatol 2001;64 (Suppl):25–7.
132. Maini R, St Clair EW, Breedveld F, Furst D,
Kalden J, Weisman M, et al. Infliximab (chimeric
anti-tumour necrosis factor monoclonal
antibody) versus placebo in rheumatoid arthritis
patients receiving concomitant methotrexate:
a randomised phase III trial. Lancet 1999;
359:1932–9.
133. Lipsky PE, van der Heijde DMFM, St Clair EW,
Furst DE, Breedveld FC, Kalden JR, et al.
Infliximab and methotrexate in the treatment of
rheumatoid arthritis. N Engl J Med 2000;
343:1594–602.
134. Maini RN, Breedveld FC, Kalden JR, Smolen JS,
Furst D, Weisman MH, et al. Sustained
improvement over two years in physical function,
structural damage, and signs and symptoms
among patients with rheumatoid arthritis treated
with infliximab and methotrexate. Arthritis Rheum
2004;50:1051–65.
135. St Clair EW, van der Heijde DM, Smolen JS,
Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate
therapy for early rheumatoid arthritis: a
randomized, controlled trial. Arthritis Rheum 2004;
50:3432–43.
136. Elliott MJ, Maini RN, Feldmann M, Kalden JR,
Antoni C, Smolen JS, et al. Randomised doubleblind
comparison of chimeric monoclonal
antibody to tumour necrosis factor (cA2) versus
placebo in rheumatoid arthritis. Lancet 1994;
334:1105–10.
137. Maini RN, Breedveld FC, Kalden JR, Smolen JS,
Davis D, Macfarlane JD, et al. Therapeutic efficacy
of multiple intravenous infusions of anti-tumour
necrosis factor monoclonal antibody combined
with low-dose weekly methotrexate in rheumatoid
arthritis. Arthritis Rheum 1998;41:1552–63.
138. Kavanaugh A, St Clair E, McCune W, Braakman T,
Lipsky P. Chimeric anti-tumor necrosis factor – a
monoclonal antibody treatment of patients with
rheumatoid arthritis receiving methotrexate
therapy. J Rheumatol 2000;27:841–50.
139. Durez P, Nzeusseu TA, Lauwerys BR,
Manicourt DH, Verschueren P, Westhovens R, et al.
A randomised comparative study of the short term
clinical and biological effects of intravenous pulse
methylprednisolone and infliximab in patients
with active rheumatoid arthritis despite
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
methotrexate treatment. Ann Rheum Dis 2004;
63:1069–74.
140. Taylor PC, Steuer A, Gruber J, Cosgrove DO,
Blomley MJ, Marsters PA, et al. Comparison of
ultrasonographic assessment of synovitis and joint
vascularity with radiographic evaluation in a
randomized, placebo-controlled study of
infliximab therapy in early rheumatoid arthritis.
Arthritis Rheum 2004;50:1107–16.
141. Quinn MA, Conaghan PG, O’Connor PJ, Karim Z,
Greenstein A, Brown A, et al. Very early treatment
with infliximab in addition to methotrexate in
early, poor-prognosis rheumatoid arthritis reduces
magnetic resonance imaging evidence of synovitis
and damage, with sustained benefit after
infliximab withdrawal: results from a twelve-month
randomized, double-blind, placebo-controlled
trial. Arthritis Rheum 2005;52:27–35.
142. Durez P, Toukap AN, Lauwerys BR, Manicourt DH,
Westhovens R, Houssiau FA. Distinct effects of
infliximab and intravenous pulse
methylprednisolone on CRP, interleukin-6 and
matrix metalloproteinase-3 serum titers in
rheumatoid arthritis patients with active disease
despite methotrexate. A prospective randomised
comparative study. Arthritis Rheum 2003;
48(9 Suppl):212.
143. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK,
Van Zeben D, Kerstens PJSM, Hazes JMW,
Zwinderman AH, et al. Treatment strategies in
early rheumatoid arthritis: clinical and
radiological outcomes after 2 year follow-up of the
BeSt study [abstract L4]. Arthritis Rheum 2004;
50(12 Suppl):4096.
144. De Vries-Bouwstra JK, Goekoop-Ruiterman YPM,
Breedveld FC, Han KH, Kerstens PJS, Ronday HK,
et al. Clinical and radiological outcomes after oneyear
follow-up of the BeSt study, a randomized
trial comparing four different treatment strategies
in early rheumatoid arthritis (RA) [abstract].
Arthritis Rheum 2003;48(Suppl):3649.
145. Armstrong RD, English J, Gibson T, Chakraborty J,
Marks V. Serum methylprednisolone levels
following intra-articular injection of
methylprednisolone acetate. Ann Rheum Dis 1981;
40:571–4.
146. FDA Arthritis Advisory Committee. Update on the
TNF- blocking agents. FDA briefing document
4 March, 2003 meeting of Arthritis Advisory
Committee. URL: http://www.fda.gov/ohrms/
dockets/ac/03/briefing/3930B1_01_B-TNF.
Briefing.pdf. Accessed 19 January 2005.
147. Symmons DPM, Silman AJ. Anti-tumor necrosis
factor therapy and the risk of lymphoma in
rheumatoid arthritis: no clear answer. Arthritis
Rheum 2004;50:1703–6.
133